TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

Trial review

SURMOUNT-OSA and Tirzepatide for Sleep Apnea

Tirzepatide in obstructive sleep apnoea with obesity

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

SURMOUNT-OSA was a two phase 3, randomised, double-blind, placebo-controlled trials under one master protocol funded by Eli Lilly and Company. Tirzepatide reduced the apnoea-hypopnoea index, body weight, hypoxic burden, hsCRP and systolic blood pressure, and improved sleep-related patient-reported outcomes. That figure belongs to the population, dose, comparator and 52 weeks shown below, and describes a group average under trial conditions rather than a prediction for any individual.

Answer last reviewed: Evidence:
SURMOUNT-OSA at a glanceVerified
Data table
DesignTwo phase 3, randomised, double-blind, placebo-controlled trials under one master protocol
PopulationAdults with moderate-to-severe obstructive sleep apnoea and obesity. Trial 1 enrolled participants not using positive airway pressure; trial 2 enrolled participants using PAP at baseline
Sample sizenot captured
InterventionTirzepatide once weekly at maximum tolerated dose
ComparatorPlacebo
Duration52 weeks
Primary endpointChange in apnoea-hypopnoea index from baseline
Main resultTirzepatide reduced the apnoea-hypopnoea index, body weight, hypoxic burden, hsCRP and systolic blood pressure, and improved sleep-related patient-reported outcomes
NCT NCT05412004 · DOI 10.1056/NEJMoa2404881 · PMID 38912654Last source check: 2026-07-24
How to read SURMOUNT-OSA without over-reading it
1Who was eligibleAdults with moderate-to-severe obstructive sleep apnoea and obesity. Trial 1 enrolled pa2What they receivedTirzepatide once weekly at maximum tolerated dose3What it was compared againstPlacebo4For how long52 weeks5What was measured firstChange in apnoea-hypopnoea index from baseline6What the group average wasTirzepatide reduced the apnoea-hypopnoea index, body weight, hypoxic burden, hsCRP and s7What it does not tell youA group average is not a prediction for any individual reader.
Show this figure as a table
Data table
StepStageWhat happens
1Who was eligibleAdults with moderate-to-severe obstructive sleep apnoea and obesity. Trial 1 enrolled participants not using positive airway pressure; trial 2 enrolled participants using PAP at baseline
2What they receivedTirzepatide once weekly at maximum tolerated dose
3What it was compared againstPlacebo
4For how long52 weeks
5What was measured firstChange in apnoea-hypopnoea index from baseline
6What the group average wasTirzepatide reduced the apnoea-hypopnoea index, body weight, hypoxic burden, hsCRP and systolic blood pressure, and improved sleep-related patient-reported outcomes
7What it does not tell youA group average is not a prediction for any individual reader.
Strip any step and the result stops meaning what the trial found.
Primary results, from the peer-reviewed publicationNew England Journal of Medicine 2024;391(13)
Intervention groupnot capturedComparator groupnot captured
Show this figure as a table
Data table
ItemWeight changeEvidence
Intervention groupnot captured
Comparator groupnot captured
Bars fill only from the peer-reviewed publication. Topline and press-release figures are labelled as such and are never charted as results.
What this trial can and cannot tell you
What this trial can and cannot tell you
QuestionPosition
Average effect in the studied populationReported once captured
Your individual outcomeNot predicted by any trial
Effect of a compounded preparationNot studied here
Effect at doses outside the protocolNot studied here
Effect after stoppingOnly if the trial included a withdrawal phase
Long-term safety beyond the trialOutside the observation window

Who was studied

SURMOUNT-OSA enrolled 469 adults with obesity (BMI 30 or more) and moderate-to-severe obstructive sleep apnea, meaning 15 or more breathing events an hour on an in-lab sleep study at screening. It ran as two trials under one protocol:

  • Trial 1 (234 people): not using positive airway pressure (PAP), because they were unable or unwilling, and off PAP for at least four weeks before screening.
  • Trial 2 (235 people): on PAP for at least three months and planning to continue.

At the start, the mean apnea-hypopnea index (AHI) was 51.5 in trial 1 and 49.5 in trial 2, and mean BMI was 39.1 and 38.7. Men made up 67.1% and 72.3%; enrolment of men was capped at 70% to make sure enough women took part. Sites were in ten countries and territories.

Not studied: people with type 1 or type 2 diabetes or an HbA1c of 6.5% or more; people with mainly central or mixed sleep apnea, obesity hypoventilation syndrome or significant craniofacial abnormalities; people with previous sleep-apnea or major ear, nose and throat surgery, or past or planned obesity surgery; pregnant or breastfeeding women; and anyone with a BMI under 30.

Sources: ClinicalTrials.gov (NCT05412004) and the full paper on PubMed Central, read November 9, 2026.

What was given, and what it was compared against

  • Tirzepatide started at 2.5 mg once a week and rose by 2.5 mg every four weeks. By week 20, people reached their maximum tolerated dose of 10 mg or 15 mg.
  • The comparator was placebo, in matching weekly injections. The trial was double-blind: participants, investigators and the sponsor did not know who was on which.
  • Randomisation was 1:1 within each trial, for 52 weeks of treatment, plus a four-week safety follow-up.
  • People in trial 2 kept using PAP but stopped it for seven days before each sleep study, so their AHI was measured off PAP.
  • Anyone who could not tolerate at least 10 mg stopped the study drug but was encouraged to stay in the trial.

Sleep was measured by in-lab polysomnography at screening, week 20 and week 52, scored centrally. Source: Malhotra et al., NEJM 2024;391:1193-1205, read on PubMed Central November 9, 2026.

Results

All results below use the treatment-regimen estimand, which counts everyone who received a dose whether or not they kept taking it. The paper uses it by default.

Primary endpoint: change in AHI (events per hour) at week 52.

  • Trial 1: −25.3 with tirzepatide against −5.3 with placebo. The difference was −20.0 (95% CI −25.8 to −14.2), P<0.001.
  • Trial 2: −29.3 against −5.5. The difference was −23.8 (95% CI −29.6 to −17.9), P<0.001.

Key secondary endpoints, controlled for multiple testing:

At week 52Trial 1: tirzepatide vs placeboTrial 2: tirzepatide vs placebo
Percent change in AHI−50.7% vs −3.0%−58.7% vs −2.5%
AHI fell by at least half61.2% vs 19.0%72.4% vs 23.3%
AHI under 5, or 5 to 14 with low daytime sleepiness42.2% vs 15.9%50.2% vs 14.3%
Body weight−17.7% vs −1.6%−19.6% vs −2.3%

Hypoxic burden, hsCRP (a marker of inflammation), systolic blood pressure and patient-reported sleep impairment and disturbance also improved significantly against placebo in both trials.

Adverse events and discontinuations

From the paper's safety table. The tirzepatide group in trial 2 counts 119 people, because one did not receive a dose.

EventTrial 1: tirzepatide / placeboTrial 2: tirzepatide / placebo
Stopped study drug because of an adverse event5 (4.4%) / 2 (1.7%)4 (3.4%) / 8 (7.0%)
Serious adverse events9 (7.9%) / 7 (5.8%)7 (5.9%) / 12 (10.5%)
Diarrhoea26.3% / 12.5%21.8% / 8.8%
Nausea25.4% / 10.0%21.8% / 5.3%
Vomiting17.5% / 4.2%9.2% / 0.9%
Constipation15.8% / 2.5%15.1% / 4.4%

There were no deaths. Gastrointestinal events were mostly mild to moderate.

Completion (ClinicalTrials.gov): in trial 1, 101 of 114 on tirzepatide (88.6%) against 86 of 120 on placebo (71.7%). In trial 2, 113 of 120 (94.2%) against 89 of 115 (77.4%). More people left the placebo groups, mostly by withdrawing themselves.

Limitations

  • Funding. Eli Lilly funded the trials, and four authors are Lilly employees.
  • Duration. Fifty-two weeks, for a condition people live with for years. The authors note that no longer treatment period was studied.
  • No outcome events. The trials were not designed to show effects on heart attacks, strokes or deaths.
  • Who was excluded. Everyone had a BMI of 30 or more, and no one had diabetes. The results say nothing about sleep apnea in people with overweight or normal weight.
  • PAP use. Trial 2 did not test whether tirzepatide changed how much people used PAP.
  • Symptoms. The trials were not designed to compare people with and without daytime symptoms at the start. The size of change in the sleep questionnaires that matters to patients has not been established.
  • Uneven dropout. More people left the placebo groups, so how missing data were handled matters.
  • Measurement. AHI came from single nights in a sleep lab, not from sleep at home over time.

How this should and should not be read

A fair reading: in adults with obesity and moderate-to-severe sleep apnea, a year of tirzepatide roughly halved the number of breathing events an hour on average, alongside about 18 to 20% weight loss.

Common misreadings:

  • "I can stop using CPAP." Trial 2 participants kept using PAP, and the trial did not test stopping it. In trial 1, the mean AHI started at 51.5 and fell by 25.3, which leaves the group average still in the moderate range.
  • "It cures sleep apnea." About half or fewer reached an AHI under 5, or a mild AHI with low daytime sleepiness. Most people still had sleep apnea.
  • "It works for everyone who snores." Only people with obesity and moderate-to-severe obstructive sleep apnea were studied.
  • "Compounded tirzepatide does this too." Only the approved product was tested. Zepbound's label covers moderate-to-severe obstructive sleep apnea in adults with obesity. Compounded tirzepatide has no approval for anything.

A cost note: people with moderate-to-severe sleep apnea are not eligible for the Medicare GLP-1 Bridge, although their Part D plan might cover a GLP-1.

How it compares with other trials

  • SURMOUNT-1 measured weight, not breathing. It reported −20.9% at 15 mg over 72 weeks (treatment-regimen estimand) in people without diabetes. SURMOUNT-OSA's −17.7% and −19.6% came over 52 weeks at maximum tolerated doses, in a population with severe sleep apnea. The durations, doses and populations differ, so the figures are not directly comparable.
  • Sleep apnea treatments. CPAP, oral appliances and surgery were not comparators here. This trial cannot say whether tirzepatide is better or worse than any of them.
  • Heart outcomes. The paper points to SURMOUNT-MMO (NCT05556512), which it described as ongoing in 2024, for evidence on cardiovascular outcomes in people with obesity.
  • SUMMIT was also placebo-controlled and double-blind, but in heart failure with preserved ejection fraction and with different endpoints. It is not a like-for-like comparison.

Questions readers actually ask

Does this mean I would lose that much weight?

No. Trials report group averages under controlled conditions with specific eligibility criteria. Individual results vary widely, and the trial population may not resemble you.

Do these results apply to compounded tirzepatide?

Not automatically. Trials studied the approved product at studied doses. A compounded preparation at a different concentration, formulation or route has not been through those trials.

Cite this pageCC BY 4.0

Tirzepatide Ranked. “SURMOUNT-OSA and Tirzepatide for Sleep Apnea.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/research/surmount-osa/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error
Comparing 0 of 4